Are you Dr. Greenhaw?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 32 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
516 Pegram Dr
Tupelo, MS 38801Phone+1 662-844-6272Fax+1 662-844-1603
Summary
- Dr. Bradley Greenhaw, MD is a board certified dermatologist in Tupelo, Mississippi. He is currently licensed to practice medicine in Mississippi, Pennsylvania, and South Carolina. He is affiliated with North Mississippi Medical Center - Tupelo.
Education & Training
Medical University of South CarolinaResidency, Dermatology, 2011 - 2014
University of Mississippi Medical CenterInternship, Internal Medicine, 2010 - 2011- University of Mississippi School of MedicineClass of 2010
Certifications & Licensure
MS State Medical License 2015 - 2025
PA State Medical License 2014 - 2016
SC State Medical License 2012 - 2015- American Board of Dermatology Dermatology
Publications & Presentations
PubMed
- 45 citationsMolecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patientsBradley N. Greenhaw, Kyle R. Covington, Sarah J. Kurley, Yıldıray Yeniay, Nhat Anh Cao
Journal of the American Academy of Dermatology. 2020-09-01 - 39 citationsEstimation of Prognosis in Invasive Cutaneous Melanoma: An Independent Study of the Accuracy of a Gene Expression Profile Test.Bradley N. Greenhaw, John A. Zitelli, David G. Brodland
Dermatologic Surgery. 2018-12-01 - 22 citationsFungal immunotherapy in patients with allergic fungal sinusitis.Bradley Greenhaw, Richard D. deShazo, Jeanette L. Arnold, Leigh Wright
Annals of Allergy, Asthma & Immunology. 2011-11-01
Press Mentions
| Newsmakers |June 20th, 2021
Castle Biosciences Announces Publication of a Systematic Review and Meta-Analysis Demonstrating DecisionDx-Melanoma Test as Independent, Significant Predictor of Recurrence and Metastatic RiskApril 1st, 2020
31-GEP Test Predicts Likelihood of Metastasis for Cutaneous MelanomaMarch 5th, 2019- Join now to see all
